Category: Drug industry

10/25/2016

Black box warnings for ‘lifesaving’ hepatitis C drugs highlight systematic misinformation

3 9/28/2016

What some stories missed about the muscular dystrophy drug approval: Pharma’s close ties to vocal patient advocacy groups

4 9/7/2016

Seven intriguing angles on the EpiPen price-gouging story

8/30/2016

Where are the TV ads to “educate” patients about the negative Opdivo lung cancer trial?

8/23/2016

What journalists and consumers should know about the tug-of-war between biologics and generic ‘biosimilars’

8/3/2016

Govt committee exploits Ice Bucket Challenge ‘breakthrough’ to plug industry-friendly ‘Cures Act’

3 6/22/2016

What’s at stake in the FDA’s decision on eteplirsen, an experimental muscular dystrophy drug

3 6/16/2016

Objective news story or “giant platform for propaganda”? The Times pushes pharma viewpoint with one-sided coverage of osteoporosis drugs

6/13/2016

21st Century Cures Act nears passage with little news media scrutiny

3 5/23/2016

Inside the Sausage Factory of Drug Approval: Nuplazid (pimavanserin) coverage didn’t inspect closely enough